Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice

Abstract Background Staphylococcus aureus (S. aureus) arthritis is one of the most detrimental joint diseases known and leads to severe joint destruction within days. We hypothesized that the provision of auxiliary immunoregulation via an expanded compartment of T regulatory cells (Tregs) could damp...

Full description

Bibliographic Details
Main Authors: Berglind Bergmann, Ying Fei, Pernilla Jirholt, Zhicheng Hu, Maria Bergquist, Abukar Ali, Catharina Lindholm, Olov Ekwall, Guillaume Churlaud, David Klatzmann, Tao Jin, Inger Gjertsson
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Infectious Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12879-020-4880-8
_version_ 1818293862865567744
author Berglind Bergmann
Ying Fei
Pernilla Jirholt
Zhicheng Hu
Maria Bergquist
Abukar Ali
Catharina Lindholm
Olov Ekwall
Guillaume Churlaud
David Klatzmann
Tao Jin
Inger Gjertsson
author_facet Berglind Bergmann
Ying Fei
Pernilla Jirholt
Zhicheng Hu
Maria Bergquist
Abukar Ali
Catharina Lindholm
Olov Ekwall
Guillaume Churlaud
David Klatzmann
Tao Jin
Inger Gjertsson
author_sort Berglind Bergmann
collection DOAJ
description Abstract Background Staphylococcus aureus (S. aureus) arthritis is one of the most detrimental joint diseases known and leads to severe joint destruction within days. We hypothesized that the provision of auxiliary immunoregulation via an expanded compartment of T regulatory cells (Tregs) could dampen detrimental aspects of the host immune response whilst preserving its protective nature. Administration of low-dose interleukin 2 (IL2) preferentially expands Tregs, and is being studied as a treatment choice in several autoimmune conditions. We aimed to evaluate the role of IL2 and Tregs in septic arthritis using a well-established mouse model of haematogenously spred S. aureus arthritis. Methods C57BL/6 or NMRI mice we intravenously (iv) injected with a defined dose of S. aureus LS-1 or Newman and the role of IL2 and Tregs were assessed by the following approaches: IL2 was endogenously delivered by intraperitoneal injection of a recombinant adeno-associated virus vector (rAAV) before iv S. aureus inoculation; Tregs were depleted before and during S. aureus arthritis using antiCD25 antibodies; Tregs were adoptively transferred before induction of S. aureus arthritis and finally, recombinant IL2 was used as a treatment starting day 3 after S. aureus injection. Studied outcomes included survival, weight change, bacterial clearance, and joint damage. Results Expansion of Tregs induced by IL2 gene therapy prior to disease onset does not compromise host resistance to S. aureus infection, as the increased proportions of Tregs reduced the arthritis severity as well as the systemic inflammatory response, while simultaneously preserving the host’s ability to clear the infection. Conclusions Pre-treatment with IL2 gene therapy dampens detrimental immune responses but preserves appropriate host defense, which alleviates S. aureus septic arthritis in a mouse model.
first_indexed 2024-12-13T03:22:36Z
format Article
id doaj.art-e37e69b8fcc745dfa3d8d446c3678010
institution Directory Open Access Journal
issn 1471-2334
language English
last_indexed 2024-12-13T03:22:36Z
publishDate 2020-02-01
publisher BMC
record_format Article
series BMC Infectious Diseases
spelling doaj.art-e37e69b8fcc745dfa3d8d446c36780102022-12-22T00:01:20ZengBMCBMC Infectious Diseases1471-23342020-02-0120111510.1186/s12879-020-4880-8Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in miceBerglind Bergmann0Ying Fei1Pernilla Jirholt2Zhicheng Hu3Maria Bergquist4Abukar Ali5Catharina Lindholm6Olov Ekwall7Guillaume Churlaud8David Klatzmann9Tao Jin10Inger Gjertsson11Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgDepartment of Microbiology and Immunology, GuiZhou Medical UniversityDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B)AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B)Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of GothenburgAbstract Background Staphylococcus aureus (S. aureus) arthritis is one of the most detrimental joint diseases known and leads to severe joint destruction within days. We hypothesized that the provision of auxiliary immunoregulation via an expanded compartment of T regulatory cells (Tregs) could dampen detrimental aspects of the host immune response whilst preserving its protective nature. Administration of low-dose interleukin 2 (IL2) preferentially expands Tregs, and is being studied as a treatment choice in several autoimmune conditions. We aimed to evaluate the role of IL2 and Tregs in septic arthritis using a well-established mouse model of haematogenously spred S. aureus arthritis. Methods C57BL/6 or NMRI mice we intravenously (iv) injected with a defined dose of S. aureus LS-1 or Newman and the role of IL2 and Tregs were assessed by the following approaches: IL2 was endogenously delivered by intraperitoneal injection of a recombinant adeno-associated virus vector (rAAV) before iv S. aureus inoculation; Tregs were depleted before and during S. aureus arthritis using antiCD25 antibodies; Tregs were adoptively transferred before induction of S. aureus arthritis and finally, recombinant IL2 was used as a treatment starting day 3 after S. aureus injection. Studied outcomes included survival, weight change, bacterial clearance, and joint damage. Results Expansion of Tregs induced by IL2 gene therapy prior to disease onset does not compromise host resistance to S. aureus infection, as the increased proportions of Tregs reduced the arthritis severity as well as the systemic inflammatory response, while simultaneously preserving the host’s ability to clear the infection. Conclusions Pre-treatment with IL2 gene therapy dampens detrimental immune responses but preserves appropriate host defense, which alleviates S. aureus septic arthritis in a mouse model.http://link.springer.com/article/10.1186/s12879-020-4880-8T regulatory cellsTregsIL2S. aureusArthritisMice
spellingShingle Berglind Bergmann
Ying Fei
Pernilla Jirholt
Zhicheng Hu
Maria Bergquist
Abukar Ali
Catharina Lindholm
Olov Ekwall
Guillaume Churlaud
David Klatzmann
Tao Jin
Inger Gjertsson
Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice
BMC Infectious Diseases
T regulatory cells
Tregs
IL2
S. aureus
Arthritis
Mice
title Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice
title_full Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice
title_fullStr Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice
title_full_unstemmed Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice
title_short Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice
title_sort pre treatment with il2 gene therapy alleviates staphylococcus aureus arthritis in mice
topic T regulatory cells
Tregs
IL2
S. aureus
Arthritis
Mice
url http://link.springer.com/article/10.1186/s12879-020-4880-8
work_keys_str_mv AT berglindbergmann pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT yingfei pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT pernillajirholt pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT zhichenghu pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT mariabergquist pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT abukarali pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT catharinalindholm pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT olovekwall pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT guillaumechurlaud pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT davidklatzmann pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT taojin pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice
AT ingergjertsson pretreatmentwithil2genetherapyalleviatesstaphylococcusaureusarthritisinmice